Interview with Jean-Luc Bélingard, CEO, Ipsen France
As the G5 brings together five very different companies – Ipsen, LFB, Pierre Fabre, Sanofi-Aventis, Servier – could you explain the origin behind the creation and the purpose of the…
Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by 3 franchises: neurology, endocrinology and urology-oncology. Ipsen’s commitment to oncology is exemplified through its growing portfolio of key therapies improving the care of patients suffering from prostate cancer, bladder cancer or neuroendocrine tumors. Ipsen also has a significant presence in primary care. Moreover, the Group has an active policy of partnerships. Ipsen’s R&D is focused on its innovative and differentiated technological platforms, peptides and toxins, located in the heart of the leading biotechnological and life sciences hubs (Les Ulis, France; Slough/Oxford, UK; Cambridge, US).
2015 has been Ipsen´s best year since becoming a publicly traded company, marked by their take-off in the US. In 2016 the US will overtake France to become their number one affiliate. Besides an excellent 2015 operating performance, sales grew by more than 10% year-on-year, driven by the successful launch of Somatuline in neuroendocrine tumors in the US and Europe, and the performance of Dysport in aesthetics. Core operating income grew by close to 24%, reflecting continuous transformation and cost monitoring efforts.
Contact
Address: 65 Quai Georges Gorse 92100, Boulogne-Billancourt,France
Tel: +33 (0)1 58 33 50 00
Web: http://www.ipsen.com/en/ipsen-worldwide
As the G5 brings together five very different companies – Ipsen, LFB, Pierre Fabre, Sanofi-Aventis, Servier – could you explain the origin behind the creation and the purpose of the…
Nycomed lost an important patent with Pantoprazole in the middle of 2009, which has undoubtedly warranted some restructuring. What has been the impact of this loss on business in France,…
BMS recently announced divesting from their facilities in Epernon and Meymac but at the same time reinforcing manufacturing in Agen. Could you speak to strategy of this restructuring within France…
You worked for many years in emerging markets, especially in Latin America, but also in neighbor countries such as Spain. How these previous experiences in very different markets can now…
In the wake of the most recent CSIS meeting, LFB and Sanofi-Aventis announced the intention to collaborate in bioproduction. What are the terms to this agreement and what are the…
Novo Nordisk just celebrated 50 years in France; what have been some of the more recent events that have marked the affiliate’s time here? If you look from the perspective…
Baxter is approaching 40 years in France, what have been the major milestones of the group during this period and what is the importance of France to the group? During…
Sandoz has set important trends in the pharmaceutical market, first by creating a leading global generics business under the umbrella of parent company Novartis, and secondly by investing heavily in…
How would you define the Institut Pasteur’s relationship with the pharmaceutical industry and how it has evolved in recent years? Since its foundation 120 years ago, the Institut Pasteur has…
Nordic Pharma has been established in the French market since 2002 as one of its first steps towards internationalization. What have been the main milestones and achievements of Nordic in…
In only four years Celgene has introduced a number of important products in the French market and is now seen as a preeminent biopharmaceutical company in hematology. As the head…
Octapharma was founded in 1983 and entered decisively in the French market in 1999, when it acquired a plasma facility in Lingolsheim, Alsace. Since then, what have been the main…
As the market leader in the French pre-wholesale market, Depolado had a quite impressive market share growth in the previous 3 years, now being responsible for a quarter of the…
See our Cookie Privacy Policy Here
